• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for the preparation of a new, physiologically active, water-soluble complex compound of hemin arginate or hemin lysinate in which crystalline hemin and the amino acid L-arginine or L-lysine, in a molar proportion of 1:3, are allowed to react at room temperature under vigorous stirring for 10 to 15 hours in a solvent mixture of acetone and water 300:20 v/v. The hemin arginate or hemin lysinate thus formed is a powdery, stable compound suitable for use as raw material in tablets or capsules or as dry substance for preparation of injections for treatment of various types of anemia, particularly anemias associated with prophyria.
    公开号:SU1384188A3
    申请号:SU3831925
    申请日:1985-01-09
    公开日:1988-03-23
    发明作者:Даниель Инберг Грелс；Лайла Анери Пенттиля Ритва；Олави Токола Рейно；Антеро Тенхунен Раймо
    申请人:Медика Фармасьютикал Компани,Лтд (Фирма)；
    IPC主号:
    专利说明:

    00 00 4ib
    00 00

    O4
    The invention relates to medicine, in particular, to methods for the preparation of physiologically active substances intended for use in tablets, capsules or for injections in the treatment of porphyria and certain types of iron deficiency anemia.
    The purpose of the invention is to obtain a more stable drug.
    The method is carried out as follows.
    A water soluble crystalline hemin is reacted with a suitable base, for example an amino acid, such as L-lysine or L-arginine in a solvent mixture containing water and acetone. The composition of the solvent, namely the ratio of organic solvent to water, is important from the point of view of the medical value of the target product. The water content of the solvent mixture is so low (about 7 / J) that neither hemin nor a sufficiently soluble L-arginine dissolve. The reaction takes place with vigorous stirring and a certain pH of the solution. The resulting product is isolated and dried. Thus, the hemin compound is obtained in the form of a bitch and it is soluble in water, which is essential both from a medical and pharmacological point of view.
    The hemin molecule carries two carboxyl groups that interact with the basic amino groups of L-lysine or L-arginine.
    The gemin-arginate and hemin-lysinate obtained by the proposed method are dissolved in water and the pH of the solutions is measured at regular intervals and these values are compared with the pH of the mechanical mixture of hemin and L-arginine dissolved in water.
    The research results are presented in Table. one,
    From tab. 1 it follows that the pH of heminarginate and hemin-lysinate is stable (pH about 8) for 24 hours. On the other hand, the pH of the mechanical mixture decreases very slowly, probably as a result of a very slow reaction between the carboxyl groups of hemin and the amino group of L-amino acid. Therefore, in this way it is impossible to obtain a product of therapeutic value. Gemin-arginate and hemin-lysinate, obtained by the proposed method, are a complex
    50

    0

    five
    compound obtained by the reaction of L-amino acid with carboxyl groups of hemin.
    To determine, on the one hand, the optimal molar ratio of the two reagents and, on the other hand, the most appropriate composition of the mixture of solvents with hemin and arginite, the following tests are carried out.
    The crystalline hemin is reacted with L-lysine or L-arginine in a molar ratio of 1: 2 and 1: 3 with vigorous stirring in a mixture of solvents comprising organic solvent and water in various ratios. The precipitated substance is filtered, washed and dried.
    The solubility of the substance in water is determined by dissolving 1.0 g of geminearginate obtained in each test in 50 ml of distilled water with vigorous stirring in
    bottom 1 hour
    The solutions are centrifuged (3500 rpm), the residue is washed with 10 ml of distilled water and 10 ml of acetone, dried and weighed. The insoluble residue is essentially unreacted hemin.
    The test results are presented in Table. 2
    The resinous substance formed in some tests can be converted to powder form. It was found that it is desirable to have a hemin to arginine or lysine ratio of 1: 3, and the preferred solvent should include 300 ml of acetone and 20 ml of water, so that the reaction between hemin and L-arginine or L-lysine occurs accordingly, a large excess of L-arginine or L-lysine is required.
    Example 1.6.26 g of crystalline hemin (0.01 M) and 3.48 g of crystalline L-arginine (0.02 M) in a laboratory beaker equipped with a mechanical stirrer and containing a mixture of solvents from 300 ml of acetone and 20 ml of water are vigorously stirred for 10 hours. The resulting product is filtered, washed with acetone and dried. The output of hemarin-arginate 9.5 g (95%). The amount of insoluble residue is determined by the described method and 0.14 g (14%) is obtained.
    PR and M e p 2. 6,52 g of crystalline hemin (0.01 M) and 4.38 g
    crystalline L-arginine (0.025 M) is treated as in Example 1, and stirring is performed for 12 hours. The yield of hemin-arginate is 11.1 g (100%), the insoluble precipitate is 0.042 g (4.2%).
    Example 6.52 g of crystalline hemin (0.01 M) and 5.23 crystalline L-arginine (0.03 M) are treated as in Example 1, and stirring is carried out for 13 hours.
    The yield of hemin-arginate 12.0 g (95%), the insoluble residue of 0.0005 g (0.05%).
    Example4. 6.52 g of kristaplic hemin (0.01 M) and 4.39 g of crystalline L-lymine (0.03 M) are treated as in Example 1, and stirring is carried out for 13 hours.
    Vykhd hemin-lysinate 10.8 g (99%), insoluble residue 0.020 g (2.8%).
    Example 5. 6.52 g of cristamine hemin (0.01 M) and 6.1 crystalline L-arginine (0.035 M) are treated as in Example 1.
    Hemin-arginate yield 12.0 g (95%), insoluble residue 0.0005 g (0.05%)
    Example In male rats, Sprague Dowley (180-250 g) caused porphyria by subcutaneous administration of 300 mg / kg of 2-allyl-2-isopropylacetamide (AIA) for 3 days. Another group of rats was treated with AIA and the germin-L-preparation complex obtained in Example 3, 10 mg / kg intraperitoneally for 3 days.
    In rat AIA rats, the daily urinary extrection of the urinary for the fobine (rve) increases from an average value of 0.08 mmol (range 0.05-0.13) to 6.79 mmol (interval 9.91-12.70), and daytime urinary excretion delta-aminolevulinic acid (ALA) from 0.20 mmol (0.15-0.23) to 7.77 mmol (2.49-11.50). On the other hand, in rats treated with D1A and the substance obtained in Example 3, an increase in urinary excretion of PBC (up to 0.28; interval 0.09-0.45 mmol / day) and ALA (up to 0.51, interval 0 23-0,83 mmol / day) less.
    Synthesis activity of delta-aminolevulinic acid (ALA) in erythro-sludge (3.96; interval 2.23-6.06 mmol ALA / 4 / 1O reticulocytes) and in the liver (15.4; interval 12.5-17 , 1 mmol) (ALA) mg protein / h) in A1A treated rats is higher than the corresponding values (1.42; interval 0.82-1.72 mmol
    Q

    0
    five
    0
    „

    five
    0
    ALA / 4/10 reticulocyte and 11.5; the interval of 9.8-13.7 mmol ALA / mg protein / h) in rats treated with AIA and the material obtained in example 3.
    The activity of hem-oxygenase (BUT) decreases to a greater degree y.AlA in the treated rats to an immeasurable level, whereas in rats treated with AIA and the material obtained in Example 3, the BUT activity is 16j2 mmol / min / mg protein (interval 9, 3-29,3).
    The porphyrinogenic effect of the AIA treatment can also be prevented by the intramuscular administration of the reMHH L-ap-gynatine complex prepared according to Example 3 at a dose of 10 mg / kg. A single intravenous administration (20 mg / kg) produces the same anti-porphyrin effect.
    Studies have shown that this drug is as effective as hematcone.
    Example 7 The biochemical effect of the stable and readily soluble heme-derivative obtained in Example 4 was studied in ten patients with acute} epatitic porphyria in the asymptomatic phase of the disease. Six patients with acute intermittent porphyria (AIP) received 2 mg (two) or 3 mg / kg / day (four) in a peripheral vein for 4 days. During treatment, the average urinary excretion of porphobilinogen fell from 194 mmol (range 60-465) to 17.2 mmol (24 4 / 7j1-30), and delta aminolevulinic acid from 133 mmol (interval 47-281) to 13, 8 mmol (24 4 / 8,1-23,4). Have four- in patients with intermittent per-) 3 mg / kg / day heme-derived median, the fecal decreased for 4 days. Protoporphins from 650 mmol / g (range 193-1140) to 89 mol / g / day dry weight (62-103) and coproporphyria from 232 mol / t (range 102-360) to 23 mmol / g dry weight (8.5-40).
    In two patients with AIP, three courses of heme (3 or 4 mg / kg / day for three or four days were carried out during an acute attack. In a 21-year-old woman, abdominal symptoms disappeared during the second day of treatment in two cases, 43 the old man with abdominal pain and peripheral neuropathy, the pain disappeared, and the neuropathy began to improve after the last of four consecutive infusions.
    Thrombophlebitis occurred in nine porphyric patients during 51 infusions. No other side effects or abnormalities in blood chemistry were found, including the study of coagulation.
    Thus, the proposed heme preparation is safe and effective in the treatment of acute hepatitis porphyria.
    Gemin Arginat0.02937/25
    Hemin-lysinate .0, 02760/25
    Gemin + b-argi-0,0160 / 25 +
    nin0,01307 / 25
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    A method of obtaining a stable water-soluble hemin-arginate or hemin-lysate complex compound for the treatment of porphyria by mixing hemin with L-arginine or L-lysine in a ratio of 1: 2-1: 3.5 and with a solvent mixture consisting of acetone and zods in the ratio of 300: 10-300: 20 at 20 ° C for 10-154.
    Table 1
    8.22 8.22 8.22 8.10 7.97 8.13
    10.13 9.81 9.33
    Table2
    eight
    Continuation of table 2
    类似技术:
    公开号 | 公开日 | 专利标题
    US4767753A|1988-08-30|Methods and compositions for preventing ulcers
    US4267194A|1981-05-12|Calcium derivatives of taurine having reinforced neuro-muscular activity
    CA1261849A|1989-09-26|L-lysine pyruvate and l-histidine pyruvate
    KR20110042165A|2011-04-25|A new metformin glycinate salt for blood glucose control
    EP0489860A1|1992-06-17|Methods and compositions for healing ulcers.
    US5023358A|1991-06-11|Vanadyl organo-mineral compound, method for obtaining such a compound, pharmaceutical composition containing this organo-mineral compound
    SU1384188A3|1988-03-23|Method of producing stable water-soluble hemin-arginate or hemin-lysate complex compound for treating porphyria
    EP0186252B1|1992-04-01| use of thiophene compounds for the manufacture of a medicament against tumours
    WO1988008715A1|1988-11-17|Method of tumor inhibition in warm-blooded animals
    US5008388A|1991-04-16|Process for preparation of a new hemin complex
    CA1058186A|1979-07-10|L-pyroglutamyl-l-prolinamide
    US4973553A|1990-11-27|Salt or organogermanium compound and medicine containing the same
    KR970008107B1|1997-05-21|Antihepatopathic composition
    US4847282A|1989-07-11|Mucolytic acetylcysteine salts
    CA1036618A|1978-08-15|Process for the manufacture of tris | ammonium-ortho-cresosyacetate
    IE903851A1|1991-05-08|Iodothyronine polymers
    CA1340006C|1998-08-18|Acylated cyanamide composition
    FR2686511A1|1993-07-30|Pharmaceutical composition containing combinations of vanadium and/or niobium with amino acids or amino acid derivatives
    US5175001A|1992-12-29|Vanadyl organo-mineral compound, method for obtaining such a compound, pharmaceutical composition containing this organo-mineral compound
    DE2819457A1|1978-11-09|L- OR DL-PHENYLGLYCINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND AGENTS CONTAINING SUCH DERIVATIVES
    CA1133471A|1982-10-12|Cephapirin salts with amino acids
    KR100344099B1|2003-09-26|Novel biphenyldicarboxylate derivative and method for manufacturing the same
    KR810000382B1|1981-04-24|Process for preparing vincamin-5-pyridoxal phosphate
    CN1027975C|1995-03-22|Compound of organo-germanium salts
    KR930007994B1|1993-08-25|Sald or organogermanium compound and medicine containing the same
    同族专利:
    公开号 | 公开日
    JPS61172821A|1986-08-04|
    BE901319A|1985-04-16|
    FR2574662A1|1986-06-20|
    SE8406263L|1986-06-11|
    DE3446887A1|1986-07-03|
    SE8406263D0|1984-12-10|
    GB8431398D0|1985-01-23|
    SE457958B|1989-02-13|
    CA1242713A|1988-10-04|
    LU85716A1|1985-07-24|
    NL192682B|1997-08-01|
    FR2574662B1|1990-03-02|
    DE3446887C2|1994-05-05|
    JPH0647541B2|1994-06-22|
    CH666273A5|1988-07-15|
    NL192682C|1997-12-02|
    ATA390784A|1989-04-15|
    NL8403782A|1986-07-01|
    AT389308B|1989-11-27|
    GB2168354B|1988-12-07|
    GB2168354A|1986-06-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2912M|1963-07-24|Rech S Pharma E R P H A R Soc|Procaine hematoporphyrinate dihydrochloride.|
    JPS4930521A|1972-07-17|1974-03-19|
    JPS538769B2|1974-10-14|1978-03-31|
    DE2527158A1|1975-06-18|1976-12-23|Herz Eberhard|MEDICINAL PRODUCTS FOR THE TREATMENT OF INFECTIOUS DISEASES AND INFLAMMATION IN HUMAN AND VETERINAL MEDICINE THAT CANNOT BE DETECTED BY MICROORGANISMS|
    JPS6021570B2|1978-07-04|1985-05-28|Sankyo Kk|
    JPS5780317A|1980-11-05|1982-05-19|Sumitomo Chem Co Ltd|Preparation of pharmaceutical composition for injection|
    JPH0160004B2|1981-06-18|1989-12-20|Shiseido Co Ltd|JPH0645681B2|1986-02-05|1994-06-15|美浜久春|Modified hem|
    IT1245890B|1991-04-12|1994-10-25|Alfa Wassermann Spa|PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.|
    US7994217B2|2002-05-02|2011-08-09|Xanodyne Pharmaceuticals, Inc.|Prenatal multivitamin/multimineral supplement|
    RU2611636C1|2016-02-25|2017-02-28|Федеральное государственное бюджетное образовательное учреждение высшего образования Новосибирский государственный аграрный университет|Hematogen|
    RU2671633C1|2017-11-30|2018-11-06|Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ"|Highly effective hematogen|
    法律状态:
    2005-05-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20040110 |
    优先权:
    申请号 | 申请日 | 专利标题
    GB08431398A|GB2168354B|1984-12-12|1984-12-12|Hemin compound|
    [返回顶部]